Biomea Fusion, Inc.公布2型糖尿病II期COVALENT-111研究52周积极结果,显示Icovamenib非慢性治疗对两个不同患者群体均有益处
Biomea Fusion, Inc.公布2型糖尿病II期COVALENT-111研究52周积极结果,显示Icovamenib非慢性治疗对两个不同患者群体均有益处
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.